AttIL2-T cell therapy

N/A

Report date: 2024/06/27 17:34:28

Base Information

Drug NameAttIL2-T cell therapy
Drug Alias NameT Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionT lymphocyte replacements
TargetsInterleukin-2
Therapy Area/IndicationsSoft Tissue NeoplasmsSarcomaOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsSoft Tissue NeoplasmsSarcomaOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A